---
title: "Zealand Pharma 因实施股票回购计划而股价上涨"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/285600065.md"
description: "在 Zealand Pharma 宣布将在未来五个月内回购近 2 亿美元的股票后，该公司的股价上涨了约 9%。该回购计划由丹斯克银行管理，将在 2026 年 5 月 7 日至 10 月 31 日期间回购最多 720 万股。此外，Zealand Pharma 预计今年将从罗氏获得 7 亿美元的里程碑付款，这与其减肥候选药物 petrelintide 有关，其中包括预计在下半年用于第三阶段试验的 5.75 亿美元和第二季度的 1.25 亿美元周年付款"
datetime: "2026-05-07T18:47:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285600065.md)
  - [en](https://longbridge.com/en/news/285600065.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285600065.md)
---

# Zealand Pharma 因实施股票回购计划而股价上涨

Shares of Zealand Pharma (ZLDPF) closed ~9% higher in Denmark after the Danish biotech announced a share buyback program to repurchase nearly $200M (DKK 1.3B) worth of its stock over the next five months. The obesity drug developer has appointed Copenhagen-based Danske Bank as lead manager for the program under which it plans to buy back up to 7.2M...

### 相关股票

- [RHHBY.US](https://longbridge.com/zh-CN/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/zh-CN/quote/RHHVF.US.md)
- [LABD.US](https://longbridge.com/zh-CN/quote/LABD.US.md)
- [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [IHI.US](https://longbridge.com/zh-CN/quote/IHI.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [DNKEY.US](https://longbridge.com/zh-CN/quote/DNKEY.US.md)

## 相关资讯与研究

- [瑞银上调爵士制药评级：核心业务韧性强劲，新药 Ziihera 成增长引擎](https://longbridge.com/zh-CN/news/286920691.md)
- [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md)
- [Scholar Rock 将出席杰富瑞全球医疗保健大会，聚焦 SMA 新药 apitegromab 关键审批](https://longbridge.com/zh-CN/news/287069556.md)
- [礼来押注非病毒基因药物，斥资 2.02 亿美元收购 Engage Bio](https://longbridge.com/zh-CN/news/287086583.md)
- [FDA 批准了 Genentech 的 Tecentriq 用于 ctDNA 指导治疗的辅助性肌肉浸润性膀胱癌 | 罗氏 (ADR) 股票新闻](https://longbridge.com/zh-CN/news/286594661.md)